– ALTO-101 demonstrated a favorable pharmacokinetic and tolerability profile; novel transdermal formulation delivered significantly greater drug exposure and fewer adverse events typically associated ...
LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the initiation of a Phase 2 double-blind, placebo-controlled study of its transdermal formulation of ...
— In the proof-of-concept study, ALTO-101 did not achieve statistical significance on primary endpoint; signals observed across EEG measures including near-significant improvement in theta-ITC ...
– ALTO-101 has been shown to positively impact cognition and key cognition-related EEG markers in humans when delivered orally – – Novel transdermal formulation of ALTO-101 exhibited favorable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results